Central Pharma joins CSafe’s network of partner pharma service providers to expand supply chain solutions for the cell and gene therapy market

CSafe and Central Pharma

Bedford UK and Monroe, OH – May 24, 2023 – CSafe, the largest active and passive temperature-controlled shipping solutions provider for the biopharmaceutical industry, and Central Pharma, a specialized service provider of manufacturing, packaging and storage for the cell and gene therapy (“CGT”) and broader biopharma markets, announced today a new partnership to provide a complementary service network to support CGT products.

The new partnership will provide expanded supply chain options for any CGT product, at any stage of development, with an initial focus on the UK and European markets.

Operating from more than 75 locations worldwide, CSafe is a proven, trusted partner for biopharmaceutical manufacturers seeking to navigate cold chain complexity, with a track record that includes precise temperature-controlled shipping of more than six billion doses of a leading COVID-19 vaccine, and 99.9% reliability across its cold chain portfolio. Central Pharma operates across UK and European markets with advanced AI software used within their specialist capabilities. From clean-room kitting to GMP filling and packing, they support warehousing storage and specialty logistics for a growing number of partners in the CGT industry.

“CSafe is excited to deepen our capabilities to serve the rapidly growing CGT market in collaboration with Central Pharma,” said CSafe CEO Patrick Schafer. “Central Pharma has earned the confidence of key CGT developers in the UK and the EU, with plans to expand their core capabilities to other markets. We know how important these therapies are to patients everywhere, and it’s our mission at CSafe to protect every shipment.”

“We’re excited to collaborate with CSafe in a sector we are deeply passionate about serving – the CGT market,” said Central Pharma CEO Alwyn Smit. “Leveraging CSafe’s consistent 40 year-history of reliability and performance, and the company’s full range of cold chain solutions, will only enhance our support for patient protection in the most complex and innovative area in medicine.”